Abstract. The function of microglia in the brain parenchyma is not fully understood. Occlusion of the middle cerebral artery (MCA) and reperfusion caused behavioral dysfunction with massive neuronal loss in the rat cerebral cortex and striatum. When exogenous microglia were microinjected into the intracerebroventricle (i.c.v.) during MCA occlusion, focal ischemia-induced behavioral dysfunction was significantly inhibited. At that time, many microglia migrated into the ischemic lesion, and microglia-derived neuron-like cells were barely detectable. These results suggest that exogenous microglia protect against focal ischemia-induced neurodegeneration and improve behavioral dysfunction.
Glial cells, such as microglia and astrocytes, have been suggested to be physiologically involved in chaperoning neurons to neuronal synaptic sites, maintaining the functional integrity of the synapse and contributing to extracellular matrix proteins (1) . On the other hand, microglia accumulate in the neighborhood of neurodegenerative sites in patients with focal cerebral ischemia (brain stroke or attack), Alzheimer's disease (AD), etc. (2) . An in vitro study of cultured microglia indicated that microglial activation induces the production of both neurotrophic and cytotoxic molecules (1) , but microglial function in the in vivo brain is not fully understood. Since microglia are macrophage-like phagocytic cells in the brain (2, 3) , it is thought that while microglia are mainly scavenger cells in the brain parenchyma, they also perform various other functions in tissue repair and neuronal regeneration (2, 4) . Previously, we determined that intracerebroventricular (i.c.v.)-injected microglia had a neuroprotective effect against neuronal death induced by 2-h occlusion of the middle cerebral artery (MCA) and reperfusion (5) . In the present study, we further examined the effect of exogenous microglia on focal brain ischemia-induced behavioral dysfunction.
Mixed glial cells (a mixture of astrocytes and microglia) were cultured from cerebral hemispheres that were carefully removed from the meninges of newborn Wistar rat brains (Slc:Wistar/ ST; SLC, Inc., Hamamatsu). Subsequently, pure microglia (over 97%) were prepared as described previously (3, 6) . Before i.c.v. injection, microglia were labeled by the fluorescent dye PKH26 (Sigma, St. Louis, MO, USA) (5). MCA occlusion was also performed in male Wistar rats (weighing approximately 300 g) as described previously (7) . Selected rats were anesthetized (sodium pentobarbital, 50 mg / kg, i.p.) and then placed in a Kopf stereotaxic frame. The microinjection coordinates (0.2 mm anterior-posterior, 1.2 mm left lateral, 3.8 mm ventral to the bregma) were according to a rat brain atlas (8) and microinjection was achieved via a 10-m l Hamilton syringe using a 22-gauge needle. At 1 h after the onset of MCA occlusion, operated rats received a microinjection of 2 m l of microglial cell suspension (approximately 50,000 cells) or vehicle control (sterilized phosphate-buffered saline, PBS). A 5-min waiting period allowed injected cells to settle before the needle was removed. The nylon thread was removed from the internal carotid artery under anesthesia at 2 h after the onset of occlusion to reperfuse the ischemic area. All animal experiments were carried out in accordance with Guide for the Care and Use of Laboratory Animals from the National Institutes of Health and The Japanese Pharmacological Society, and the protocols were approved by the Committee for Animal Research at Kyoto Pharmaceutical University.
After focal brain ischemia with or without injection of exogenous microglia, behavioral dysfunction was assessed. Briefly, rota-rod performance (Treadmill accelerating model 7750; Ugo Basile, Varese, Italy) was measured at 3 and 5 days after injection, and ipsilateral rotation induced by methamphetamine (2.5 mg / kg, i.p.; Dainippon Pharmaceutical Co., Ltd., Osaka) was assessed at 7 days. The duration of endurance on the rota-rod and the number of methamphetamine-induced rotations are given as the mean ± standard error of the mean (S.E.M.). The significance of differences was determined by an analysis of variance (ANOVA). Further statistical analysis for post hoc comparisons was performed using the Bonferroni / Dunn test (StatView; Abacus Concepts, Berkeley, CA, USA). On the other hand, endurance performance (percentage of walking surviving rats) was calculated by the Kaplan-Meier method. The statistical significance of differences was analyzed by the log-rank (Mantel-Cox) test.
After 8 days, treated rats were perfused through the aorta with 150 ml of 10 mM phosphate-buffered saline (PBS), followed by 300 ml of a cold fixative consisting of 4% paraformaldehyde, 0.35% glutaraldehyde, and 0.2% picric acid in 100 mM phosphate buffer (PB), under deep anesthesia with pentobarbital (100 mg / kg, i.p.). After perfusion, the brain was quickly removed and postfixed for 2 days with paraformaldehyde in 100 mM PB and then transferred to 15% sucrose solution in 100 mM PB containing 0.1% sodium azide at 4°C. The brain pieces were cut 20-mm-thick using a cryostat and collected in 100 mM PBS containing 0.3% Triton X-100 (PBS-T). Brain slices were incubated with primary antibody against ionized calcium binding adapter molecule-1 (Iba1, diluted 1:5,000; Wako Pure Chemical Industries, Inc., Osaka), cluster of differentiation antigen-11b (CD11b, 1:1,000; Harlan Sera-Lab, Loughbrough, England), glial cell line-derived neurotrophic factor (GDNF, 1:100; Santa Cruz Biotechnology, Santa Cruz, CA, USA), or microtubule-associated protein-2 (MAP2, 1:1,000; Sigma) for 3 days at 4°C. After several washes, sections were incubated with the appropriate secondary antibody (1:2,000) linked to fluorescein isothiocyanate (FITC) for 2 h at room temperature. All of the sections were washed several times with PBS-T between each incubation, fluorescence for FITC and PKH26 was observed using a laser scanning confocal microscope LSM410 (Carl Zeiss, Jena, Germany).
MCA occlusion and reperfusion markedly induced neuronal death in both the striatum and frontal cortex (5, 7) . Therefore, this brain insult causes behavioral dysfunction. Spontaneous motor recovery by exogenous microglia was assessed by rota-rod performance. Shamoperated rats usually remained on the rotating rod for over 150 s with a stepwise increase in speed. In contrast, MCA-ischemic rats with vehicle-injection exhibited a significant reduction in both endurance and percentage of walking rats on the rotating rod (Fig. 1) . On the other hand, ischemic rats injected with exogenous microglia (50,000 cells) showed significant endurance on the rotating rod at days 3 and 5 (Fig. 1) .
The administration of methamphetamine has been shown to induce DA release predominantly in native striatum (9, 10) ; and in this study, the administration of methamphetamine caused ipsilateral rotation in MCAischemic rats (Fig. 2) . In contrast, naive and shamoperated rats did not rotate with methamphetamine, since equal amounts of DA were released in the left and right striata (9) . When MCA-ischemic rats were injected with exogenous microglia, methamphetamine-induced ipsilateral rotation was significantly decreased (Fig. 2: A  and B) .
Previously, we reported that PKH26-labeled cells were detected in the ischemic core and were also immunostained by anti-CD11b antibody (5) . In the present study, we performed further immunocytochemical analysis using other antibodies such as Iba1 (11), MAP2 (7), and GDNF. In the in vivo normal brain, resting microglia were highly branched and had a ramified shape (Fig. 3A) . In the in vitro culture, normal microglia attached to culture dishes were rodlike or had bushy shapes with shorter and thicker processes (data not shown). When cultured microglia were detached from dishes for the i.c.v. injection, microglia immediately changed to an ameboid shape with rounded and swollen cell bodies (data not shown). In the ischemic core of the striatum after 8 days, many PKH26-labeled ameboid microglia were immunostained by anti-Iba1 antibody (Fig. 3B) , similar to the results with antiCD11b antibody, a microglia-specific standard marker (5). In comparison with normal ramified microglia in the contralateral naive striatum (Fig. 3: A and D) , immunoreactivity for GDNF was markedly detected in reactive ameboid microglia in the ischemic core (Fig. 3E) . Most interestingly, very few PKH26-labeled cells were immunostained by anti-MAP2 antibody, a neuron-specific marker, in the ischemic core (Fig. 3F) .
In this ischemic model, since left striatal neurons were massively lost, ipsilateral dopaminergic neurons in the substantia nigra were retrogradely damaged (data not shown). Therefore, microglia were also activated in the ipsilateral substantia nigra. At that time, several populations of nigral microglia that were double-labeled with PKH26 and Iba1 (Fig. 3C ), or CD11b (data not shown), were detected, suggesting that exogenous microglia may also migrate into damaged substantia nigra pars compacta. In addition, we measured the MAP2-immunopositive area in coronal sections 0.60-mm anterior from the bregma. As in our previous report (5), the i.c.v. injection of microglia (about 50,000 cells / site) significantly inhibited the focal ischemia-induced loss of neural area (data not shown).
Although neural stem cells and embryonic stem cells have been widely discussed as optimal cell sources in cell therapy for neurodegenerative disorders, such as Parkinson's disease, AD, and brain stroke (4), the usefulness of microglia in cell therapy is not fully understood. In our previous study, when microglia were injected i.c.v. at 1 h after the onset of MCA occlusion (halfway through occlusion), exogenous microglia migrated into the ischemic lesions (5) . In the present study, although focal brain ischemia caused behavioral dysfunction, the i.c.v. injection of exogenous microglia significantly rescued spontaneous motor and behavioral symmetry. While endogenous microglia accumulated and were activated in the ischemic core, massive neurodegeneration occurred, suggesting that the activation of only endogenous microglia may not be enough to protect against neurodegeneration. On the other hand, although the injection of excessive microglia (400,000 -500,000 cells) did not show any neuroprotective effect, they also did not exacerbate neuronal death (data not shown). Preliminarily the injection of undifferentiated mouse embryonic stem cells, instead of microglia, did not reduce ischemia-induced neuronal loss. These observations suggest that an appropriate number of exogenous microglia have a neuroprotective effect.
Thus, microglia exhibited specific affinity for neurodegenerative regions and had neuroprotective effects following i.c.v. or peripheral injection, without direct transplantation to the brain parenchyma (12) . Activated microglia produce neurotrophic factors and modify the response to injury or assist in structural repair (1, 2, 4, 13) . In fact, GDNF immunoreactivity was markedly detected in activated microglia in the ischemic region (Fig. 3D) . Since injected microglia were already in the ameboid form, exogenous microglia may immediately migrate into the ischemic core. Subsequently, these microglia may produce neuroprotective factors, such as GDNF, and inhibit focal ischemia-induced neuronal death and behavioral dysfunction. Therefore, cell therapy using microglia may be a powerful tool for treating brain ischemia.
More recently, Yokoyama et al. suggested that in vitro-cultured microglia were dedifferentiated under low glucose conditions with a high concentration of fetal bovine serum (14) . Among these dedifferentiated cells, surprisingly, a small population turned into neurons under subsequent serum-free conditions, while others became astrocytes, oligodendrocytes, or microglia (14) . Thus, microglia may have the potential to dedifferentiate and then turn into neurons. However, it is unknown whether this microglial potential is present in the in vivo brain. In this study, we detected a few PKH26-labeled MAP2-immunopositive cells in the ischemic core. Therefore, there is a possibility that microglia can redifferentiate into neurons even in the in vivo brain under severe ischemic conditions. However, almost all other PKH26-labeled cells were immunopositive for Iba1 and CD11b, which are specific markers for microglia and macrophages (5, 11) . Based on these observations, we consider that the neuroprotection observed in this study may be induced predominantly by exogenous microglia Fig. 3 . Confocal microscopy analysis. Isolated rat microglia were labeled by the fluorescent dye PKH26. Subsequently, 50,000 microglial cells were injected i.c.v. midway through MCA occlusion. After 8 days, rat brains were fixed and frontal and mid brain slices including the striatum (ST) and substantia nigra (SN) were then immunostained by antibodies (green, first panels) to Iba1 (A -C), GDNF (D, E), and MAP2 (F). Second panels: PKH26 fluorescence for exogenous microglia (red). Third panels: merged image. Scale bar, 40 mm.
that have migrated into the ischemic area, rather than by dedifferentiated microglia and microglia-derived neuron-like cells. In the near future, if an efficient method to induce the re-differentiation of microglia to neurons is established, it may be a potent strategy for the treatment of neurodegenerative disorders.
In conclusion, MCA occlusion and reperfusion caused behavioral dysfunction. The i.c.v. injection of exogenous microglia significantly reduced both behavioral dysfunction in spontaneous motor activity and methamphetamine-induced rotational asymmetry. In addition, activated microglia migrated into ischemic regions and reduced neurodegeneration. These results suggest that microglial transplantation may also be useful in brain stroke.
